Excess glycaemic excursions after an oral glucose tolerance test compared with a mixed meal challenge and self-measured home glucose profiles: Is the OGTT a valid predictor of postprandial hyperglycaemia and vice versa?

Diabetes, Obesity and Metabolism

Volumn 11, Issue 3, 2009, Pages 213-222

  Meier, Juris J ^a   Baller, B ^a   Menge, B A ^a   Gallwitz, B ^a,b   Schmidt, W E ^a   Nauck, M A ^c  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c DIABETESZENTRUM BAD LAUTERBERG   (Germany)

Author keywords

IGT; Insulin secretion; OGTT; Postprandial hyperglycaemia

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC VALUE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INTERMETHOD COMPARISON; ORAL GLUCOSE TOLERANCE TEST; POSTPRANDIAL STATE; PREDICTION; SELF EXAMINATION; TEST MEAL;

EID: 59349092016     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00922.x     Document Type: Article

References (36)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29 (Suppl.1): S43-S48.
2. Rolka DB, Narayan KM, Thompson TJ et al. Performance of recommended screening tests for undiagnosed diabetes and dysglycemia. Diabetes Care 2001; 24: 1899-1903.
3. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
4. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.
5. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999; 22: 920-924.
6. Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL. Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care 2001; 24: 1397-1402.
7. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia 2003; 46 (Suppl. 1): M9-M16; Epub 2002 Nov 7.
8. Ceriello A. Postprandial hyperglycemia and diabetes complications: Is it time to treat? Diabetes 2005; 54: 1-7.
9. Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 1999; 144: 229-235.
10. Temelkova-Kurktschiev TS, Koehler C, Leonhardt W et al. Increased intimal-medial thickness in newly detected type 2 diabetes: Risk factors. Diabetes Care 1999; 22: 333-338.
11. Zimmerman BR. Postprandial hyperglycemia: Implications for practice. Am J Cardiol 2001; 88: 32H-36H.
12. Ratner RE. Controlling postprandial hyperglycemia. Am J Cardiol 2001; 88: 26H-31H.
13. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
14. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
15. Wolever TM, Chiasson JL, Csima A et al. Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal versus 75 g oral glucose. Diabetes Care 1998; 21: 336-340.
16. Horowitz M, Harding PE, Maddox AF et al. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989; 32: 151-159.
17. Meier JJ, Kemmeries G, Holst JJ, Nauck MA. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 2005; 54: 2212-2218.
18. Meier JJ, Gallwitz B, Salmen S et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 2719-2725.
19. Westphal S, Kastner S, Taneva E, Leodolter A, Dierkes J, Luley C. Postprandial lipid and carbohydrate responses after the ingestion of a casein-enriched mixed meal. Am J Clin Nutr 2004; 80: 284-290.
20. Normand S, Khalfallah Y, Louche-Pelissier C et al. Influence of dietary fat on postprandial glucose metabolism (exogenous and endogenous) using intrinsically (13)C-enriched durum wheat. Br J Nutr 2001; 86: 3-11.
21. Meier JJ, Nauck MA. Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab Res Rev 2005; 21: 91-117.
22. Nauck MA, El-Ouaghlidi A, Gabrys B et al. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regul Pept 2004; 122: 209-217.
23. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76: 912-917.
24. Toft-Nielsen MB, Damholt MB, Madsbad S et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-3723.
25. Vollmer K, Holst JJ, Baller B et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2007; 5: 5.
26. Meier JJ, Hücking K, Holst JJ, Deacon CF, Schmiegel WH, Nauck MA. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 2001; 50: 2497-2504.
27. D'Orazio P, Burnett RW, Fogh-Andersen N et al. Approved IFCC recommendation on reporting results for blood glucose (abbreviated). Clin Chem 2005; 51: 1573-1576.
28. Bock G, Dalla Man C, Campioni M et al. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 2006; 55: 3536-3549.
29. Meyer C, Pimenta W, Woerle HJ et al. Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care 2006; 29: 1909-1914.
30. Kirkman MS, Shankar RR, Shankar S et al. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: The Early Diabetes Intervention Program. Diabetes Care 2006; 29: 2095-2101.
31. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
32. Meier JJ, Deifuss S, Klamann A, Launhardt V, Schmiegel WH, Nauck MA. Plasma glucose at hospital admission and previous metabolic control determine myocardial infarct size and survival in patients with and without type 2 diabetes: The Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA). Diabetes Care 2005; 28: 2551-2553.
33. Gerstein HC, Pogue J, Mann JF et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: A prospective epidemiological analysis. Diabetologia 2005; 48: 1749-1755; Epub 2005 Jul 30.
34. Norhammar A, Tenerz A, Nilsson G et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: A prospective study. Lancet 2002; 359: 2140-2144.
35. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 2003; 290: 486-494.
36. Vilsboll T, Krarup T, Sonne J et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003; 88: 2706-2713.